No Data
H.C. Wainwright Maintains Poseida Therapeutics(PSTX.US) With Buy Rating, Maintains Target Price $20
H.C. Wainwright analyst Arthur He CFA maintains $Poseida Therapeutics(PSTX.US)$ with a buy rating, and maintains the target price at $20.According to TipRanks data, the analyst has a success rate of 5
Analysts Offer Insights on Healthcare Companies: Poseida Therapeutics (PSTX), Greenwich LifeSciences (GLSI) and ACELYRIN, INC. (SLRN)
Express News | Poseida Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results
Piper Sandler Reaffirms Their Buy Rating on Poseida Therapeutics (PSTX)
Poseida Therapeutics: A Strong Buy on Robust Pipeline, Strategic Partnerships, and Leadership Enhancements
Express News | Poseida Therapeutics Inc: Expects Current Cash, Cash Equivalents and Short-Term Investments Sufficient to Fund Operations Into Second Half of 2025